title: Angiotensin-converting enzyme inhibition changes the metabolic response to neuroglucopenic stress.
abstract: Neuroglucopenia induced by 2-deoxy-D-glucose (2DG) activates hypothalamic glucoreceptors leading to increased hepatic glucose production and insulin inhibition. This response is similar to what is observed with intravenous injection of angiotensin II (Ang II). However, the involvement of an angiotensin-converting enzyme inhibitor on neuroglucopenia has not been investigated. The aim of this study was to determine the effects of chronic enalapril treatment on plasma glucose, insulin and lipid levels in response to neuroglucopenia. Male Holtzman rats (120-170 g) were chronically treated with enalapril (10 mg/kg per day) in the drinking water for two weeks. On the day of experiment the animals received an i.v. enalapril final dose one hour before the neuroglucopenic stress by 2DG infusion (500 mg/kg), and blood samples were drawn before and 5, 10, 20, 30 and 60 minutes following infusion. The hyperglycaemic response to 2DG was not significantly changed by enalapril treatment. The enalapril-treated group exhibited a peak of plasma insulin higher than controls. Plasma triglyceride showed a significant increase only in the enalapril group after neuroglucopenic stress (p < 0.05).These data show that chronic enalapril treatment changes insulin and triglyceride responses to neuroglucopenia, suggesting an effect on glucose-induced insulin secretion and the storage of triglycerides.
authors.affiliation: Department of Internal Medicine, School of Medicine, Federal University of Minas Gerais, Brazil.
authors.forename: Paulo Augusto
authors.initials: PA
authors.lastname: Carvalho Miranda
authors.forename: Ana Cristina
authors.initials: AC
authors.lastname: Simões E Silva
authors.forename: Junia Ribeiro
authors.initials: JR
authors.lastname: de Oliveira Longo
authors.forename: Marcos
authors.initials: M
authors.lastname: Magalhães Madureira
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Bastos Fóscolo
authors.forename: Lucas José
authors.initials: LJ
authors.lastname: Campos Machado
authors.forename: Walkíria Wingester
authors.initials: WW
authors.lastname: Vilas Boas
authors.forename: Robson Augusto
authors.initials: RA
authors.lastname: Dos Santos
authors.forename: Candido
authors.initials: C
authors.lastname: Celso Coimbra
authors.forename: Antônio
authors.initials: A
authors.lastname: Ribeiro-Oliveira
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D003847:Deoxyglucose / Q000008:administration & dosage / Q000494:pharmacology; D004327:Drinking Behavior / Q000187:drug effects; D004656:Enalapril / Q000008:administration & dosage / Q000494:pharmacology; D005947:Glucose / Q000378:metabolism*; D007328:Insulin / Q000097:blood; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology*; D007703:Peptidyl-Dipeptidase A / Q000378:metabolism*; D051381:Rats; D013312:Stress, Physiological / Q000187:drug effects*; D013997:Time Factors; D014280:Triglycerides / Q000097:blood; D015430:Weight Gain / Q000187:drug effects
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D001786:Blood Glucose; D007328:Insulin; D014280:Triglycerides; D004656:Enalapril; D002784:Cholesterol; D003847:Deoxyglucose; D007703:Peptidyl-Dipeptidase A; D005947:Glucose